摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cinnolin-5-ol | 100949-04-0

中文名称
——
中文别名
——
英文名称
cinnolin-5-ol
英文别名
5-Cinnolinol
cinnolin-5-ol化学式
CAS
100949-04-0
化学式
C8H6N2O
mdl
——
分子量
146.148
InChiKey
ZZVUPNFZGYTAAN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    cinnolin-5-ol 在 ammonium hydrogen sulfite 、 作用下, 生成 5-Amino-cinnolin
    参考文献:
    名称:
    五线谱。第三十四部分 5-,6-和7-羟基,5-,6-和7-氨基
    摘要:
    DOI:
    10.1039/jr9550002100
  • 作为产物:
    描述:
    5-methoxy-cinnoline氢溴酸 作用下, 生成 cinnolin-5-ol
    参考文献:
    名称:
    五线谱。第三十四部分 5-,6-和7-羟基,5-,6-和7-氨基
    摘要:
    DOI:
    10.1039/jr9550002100
点击查看最新优质反应信息

文献信息

  • [EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
    申请人:NISSAN CHEMICAL IND LTD
    公开号:WO2009057827A1
    公开(公告)日:2009-05-07
    Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
    翻译结果为:新型的哒嗪酮化合物,其化学公式为(I),能够抑制嘌呤能P2X7受体,并对预防、治疗和改善炎症性和免疫性疾病有益。
  • [EN] 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS<br/>[FR] UTILISATION DE COMPOSES HETEROARYLES A SUBSTITUTION 3-ALKYLIDENEHYDRAZINO EN TANT QU'ACTIVATEURS DU RECEPTEUR DE LA THROMBOPOIETINE
    申请人:NISSAN CHEMICAL IND LTD
    公开号:WO2004108683A1
    公开(公告)日:2004-12-16
    A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14; aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10; alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14; aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
    化合物的结构式(1)如下:其中A是氮原子或CR4,B是氧原子、硫原子或NR9(但当A是氮原子时,B不是NH),R1是C2-14芳基,L1是键,CR10R11、氧原子、硫原子或NR12,X是OR13、SR13或NR14NR15,R2是氢原子、甲酰基、C1-10烷基或类似物,L2是键或类似物,L3是键,CR17R18、氧原子、硫原子或NR19,L4是键,CR20R21、氧原子、硫原子或NR22,Y是氧原子、硫原子或NR23,R3是C2-14芳基、化合物的互变异构体、前药或药学上可接受的盐或其溶剂化合物。
  • ALPHA-SUBSTITUTED VINYLTIN COMPOUND
    申请人:Tatsuta Kuniaki
    公开号:US20090023939A1
    公开(公告)日:2009-01-22
    To provide α-substituted vinyltin useful for the search for function-developing substances such as pharmaceuticals/agrichemicals and functional materials and for the construction of a compound library. An α-substituted vinyltin compound represented by the formula (1), a tautomer or salt of the compound or a solvate thereof: R 2 CH═C(R 3 )Sn(R 1 ) 3 (1) wherein R 1 is a C 1-10 alkyl group, a C 2-14 aryl group or the like, R 2 is a C 2-14 aryl group, a C 2-9 heterocyclyl group, a C 3-10 cycloalkyl group or the like, and R 3 is a carbamoyl group, a thiocarbamoyl group, an isocyanate group, an isothiocyanate group, a formylamino group, a thioformylamino group, an isonitrile group, an urea group, a carbamate group or the like.
    提供α-取代的乙烯基锡,用于寻找功能发展物质,如药物/农药和功能材料,以及用于构建化合物库。由下式表示的α-取代的乙烯基锡化合物(1)或其互变异构体或盐或溶剂合物:R2CH═C(R3)Sn(R1)3(1)其中R1是C1-10烷基,C2-14芳基或类似物,R2是C2-14芳基,C2-9杂环基,C3-10环烷基或类似物,R3是氨基甲酰基,硫氨基甲酰基,异氰酸酯基,异硫氰酸酯基,甲酰氨基基,硫代甲酰氨基基,异腈基,脲基,氨基甲酸酯基或类似物。
  • OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST
    申请人:Shibasaki Masakatsu
    公开号:US20100298559A1
    公开(公告)日:2010-11-25
    There is provided a novel optically active dinickel complex and/or a production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst. An optically active dinickel complex of Formula (I) or Formula (I′): [where R 0 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each independently a hydrogen atom, a halogen atom, a C 1-10 alkyl group or a C 1-10 alkoxy group, etc., R 2 and R 3 together form, together with a benzene ring bonded to them, a naphthalene ring, etc. A novel production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst.
    提供了一种新型光学活性二镍配合物和/或使用该二镍配合物作为催化剂进行不对称Mannich反应制备光学活性胺的生产方法。公式(I)或公式(I′)的光学活性二镍配合物:[其中R0、R1、R2、R3、R4、R5、R6和R7分别独立地是氢原子、卤素原子、C1-10烷基或C1-10烷氧基等,R2和R3连同与它们结合的苯环形成萘环等。使用该二镍配合物作为催化剂,通过不对称Mannich反应制备光学活性胺的新型生产方法。
  • Benzoxazinone derivatives, their preparation and use
    申请人:——
    公开号:US20040063704A1
    公开(公告)日:2004-04-01
    The present invention relates to novel compounds of formula (1) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C 1-6 alkoxy, arylC 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkoxyC 1-6 -alkyl, C 3-7 cycloalkylC 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyloxy, C 1-6 alkylsulfonylC 1-6 alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC 1-6 alkyl, C 1-6 alkylsulfonamido, C 1-6 alkylamido, C 1-6 alkylsulfonamidoC 1-6 alkyl, C 1-6 alkylamidoC 1-6 alkyl, arylsulfonamido, arylcarboxamido, arylsullonamidoC 1-6 alkyl, arylcarboxamidoC 1-6 alkyl, aroyl, arylC 1-6 alkyl, arylC 1-6 alkanoyl, a group R 3 OCO(CH 2 ) s , R 3 CON(R 4 )(CH 2 ) s , R 3 R 4 NCO(C 2 ) s or R 3 R 4 NSO 2 (CH 2 ) where each of R 3 and R 4 independently represents a hydrogen atom or C 1-4 alkyl or R 3 and R 4 form part of a C 1-6 azacyloalkane or C 3- 6 (2-oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Ar 1 Z, wherein Z represents a single bond, O, S or CH 2 and Ar 1 represents a phenyl or a monocyclic heteroaromatic group, said Ar 1 group being optionally substituted by 1-3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkanoyl; when Ar is a phenyl or a monocyclic heteroaromatic group, substitutents positioned ortho to one another may be linked to form a 5- or 6-membered ring: R 1 is hydrogen, C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl or arylC 1-6 alkyl; R 2 is halogen, C 1-6 alkyl, cyano, CF 3 , C 1-6 alkanoyl, C 1-6 alkoxy or hydroxy; X is CH or N; Y is a single bond, O, or C═O; p is 0, 1 or 2; r is 0, 1, 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2. Processes for preparing the compounds, pharmaceutical compositions containing them and their use as medicaments for various CNS disorders, including deression and/or anxiety, are also disclosed.
    本发明涉及公式(1)的新化合物或其药学上可接受的盐,其中Ar是苯基,萘基,单环杂芳基或双环杂芳基,所述Ar基可以选择性地被1-4个取代基取代,这些取代基可以相同或不同,选自以下群组:卤素,羟基,氰基,硝基,三氟甲基,三氟甲氧基,C1-6烷基,三氟甲磺酰氧基,五氟乙基,C1-6烷氧基,芳基C1-6烷氧基,C1-6烷硫基,C1-6烷氧基C1-6烷基,C3-7环烷基C1-6烷氧基,C1-6酰基,C1-6烷氧羰基,C1-6烷基磺酰基,C1-6烷基亚磺基,C1-6烷基磺酰氧基,C1-6烷基磺酰基C1-6烷基,芳基磺酰基,芳基磺酰氧基,芳基磺酰基C1-6烷基,C1-6烷基磺酰胺基,C1-6烷基酰胺基,C1-6烷基磺酰胺基C1-6烷基,C1-6烷基酰胺基C1-6烷基,芳基磺酰胺基,芳基羧酰胺,芳基磺酰胺基C1-6烷基,芳基羧酰胺基C1-6烷基,酰基,芳基C1-6烷基,芳基C1-6酰基,一个R3OCO(CH2)s,R3CON(R4)(CH2)s,R3R4NCO(C2)s或R3R4NSO2(CH2)组,其中R3和R4各自独立地表示氢原子或C1-4烷基,或R3和R4构成C1-6氮杂环烷或C3-6(2-氧代)氮杂环烷环,s表示零或1-4的整数,以及一个Ar1Z基,其中Z表示单键,O,S或CH2,Ar1表示苯基或单环杂芳基,所述Ar1基可以选择性地被1-3个取代基取代,这些取代基可以相同或不同,选自以下群组:卤素,羟基,氰基,三氟甲基,C1-6烷基,C1-6烷氧基或C1-6酰基;当Ar是苯基或单环杂芳基时,相对位于一个环上的取代基可以连接形成5-或6-成员环;R1是氢,C1-6烷基,C3-6烯基,C3-6炔基或芳基C1-6烷基;R2是卤素,C1-6烷基,氰基,CF3,C1-6酰基,C1-6烷氧基或羟基;X是CH或N;Y是单键,O或C═O;p是0,1或2;r是0,1,2或3;m是2,3或4;n和q独立地为1或2。还公开了制备这些化合物的方法,包含它们的制药组合物以及它们作为治疗各种中枢神经系统疾病,包括抑郁和/或焦虑的药物的用途。
查看更多